Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable April 24, 2026, to shareholders of record on March 27, 2026.
The Board of Directors approved the dividend on February 24, 2026; the payment and record dates are specified for shareholder planning.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference in Boston on March 3, 2025 at 1:50 p.m. ET. The presentation will be webcast and accessible via Danaher's Investors site under Events & Presentations.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Danaher (NYSE: DHR) reported Q4 2025 net earnings of $1.2 billion ($1.66 per diluted share) and full‑year net earnings of $3.6 billion ($5.03 per diluted share).
Q4 revenue rose 4.5% to $6.8 billion; FY2025 revenue was $24.6 billion (+3.0%). Non‑GAAP adjusted EPS grew ~4% Q4 and 4.5% FY. Operating cash flow was $2.1 billion in Q4 and $6.4 billion for FY; non‑GAAP free cash flow was $1.8 billion Q4 and $5.3 billion FY.
The company launched new products across bioprocessing, mass spectrometry, and diagnostics and initiated FY2026 guidance: core revenue +3–6% and adjusted EPS $8.35–8.50.
Danaher (NYSE: DHR) announced that CEO Rainer M. Blair will comment on fourth quarter 2025 results at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PT, with the presentation webcast on the company's Investors site.
For Q4 2025, Danaher expects estimated revenues to increase in the mid-single digit percent range year-over-year and non-GAAP core revenue growth toward the high end of its prior low-single digit guidance. For full-year 2025, the company expects non-GAAP adjusted diluted EPS toward the high end of its guidance range of $7.70 to $7.80. The company reiterated strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
Danaher (NYSE: DHR) said its President and Chief Executive Officer, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 11:15 a.m. PT.
The presentation will be simultaneously webcast and accessible from the company's Investors site under Events & Presentations at www.danaher.com.
Danaher (NYSE: DHR) will webcast its Fourth Quarter 2025 earnings conference call on Wednesday, January 28, 2026 at 8:00 a.m. ET, with an expected duration of about one hour.
The company will discuss financial performance and future expectations. The live webcast and accompanying slide presentation will be available in the Investors > Events & Presentations section at www.danaher.com. Webcast slides, the earnings press release, and related materials will be posted beginning at 6:00 a.m. ET on the day of the call.
Dial-in access: 800-245-3047 (U.S.) or +1 203-518-9765 (outside U.S.); Conference ID: DHRQ425. A replay of the webcast and call will be available after the presentation; the call replay remains available until February 11, 2026.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.32 per share. The dividend is payable on January 30, 2026 to holders of record on December 26, 2025.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:00 a.m. GMT.
The event will be simultaneously webcast and accessible via www.danaher.com, allowing investors and analysts to view the presentation live.